Stock Detail
ZYMOGENETICS INC
Biotechnology
ZGEN @ Yahoo Finance | ZGEN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $9.76 | $9.76 | $0.00 | 0.00% | 0.00 | $9.76 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.00 | $0.00 | 0 | 0 | 0 | -244.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 16.27 | 13.02 | 6.51 | 3.26 | -3.25 |
Stock Profile
ZymoGenetics, Inc. engages in the discovery, development, and commercialization of therapeutic protein-based products for the treatment of human diseases. Its products include Novolin and NovoRapid marketed worldwide for the treatment of diabetes; NovoSeven marketed worldwide for the treatment of hemophilia; Regranex for the treatment of wound healing; GlucaGen for use as an aid for gastrointestinal motility inhibition and for the treatment of severe hypoglycemia in diabetic patients treated with insulin; and Cleactor for the treatment of myocardial infarction or heart attacks. The company's product pipeline comprises rhThrombin, TACI-Ig, and IL-21. rhThrombin is a topical hemostatic agent intended for the control of bleeding during surgical procedures has completed Phase 2 clinical trial. TACI-Ig is a soluble receptor for the treatment of autoimmune diseases and is developed in collaboration with Serono S.A. IL-21 is a protein for the treatment of cancer. ZymoGenetics was co-founded by Earl W. Davie, Benjamin D. Hall, and Michael Smith in 1981. The company is headquartered in Seattle, Washington.